Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Acidic leucine-rich nuclear phosphoprotein 32 family member E (ANP32E) is a small, evolutionarily conserved nuclear protein characterized by an N-terminal leucine-rich repeat domain and a C-terminal acidic region[2][5]. Its principal function is as a histone chaperone, particularly for H2A.Z, facilitating the removal of H2A.Z from chromatin and stabilizing the H2A.Z-H2B dimer in the cytoplasm and nucleoplasm[1][3][4][6]. Unlike classical chromatin remodelers, ANP32E is not a stable component of major chromatin remodeling complexes but acts to buffer and stabilize soluble H2A.Z in a cell cycle-dependent manner, ensuring proper nuclear import and chromatin incorporation of H2A.Z[3][4]. ANP32E also inhibits protein phosphatase 2A (PP2A) activity and may participate in apoptotic regulation and intracellular transport pathways[2][6]. Dysregulation of ANP32E has been implicated in cancer cell proliferation, with context-dependent roles that may be oncogenic[3][5]. No drugs, biomarkers, or safety data are currently documented for direct targeting of ANP32E as a therapeutic target.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Acidic leucine-rich nuclear phosphoprotein 32 family member E (ANP32E).